专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

161. 发明申请

US20120093934A1 METHODS FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERES 审中-公开
标题翻译：使用生物易生物吸收纳米微粒治疗自身免疫疾病的方法
公开(公告)号：US20120093934A1
公开(公告)日：2012-04-19
申请号：US13249105
申请日：2011-09-29
申请人： Pedro Santamaria
发明人： Pedro Santamaria
IPC分类号： A61K9/16 , G01N33/566 , G01N33/567 , A61K39/385 , A61P37/04 , B82Y5/00
CPC分类号： A61K39/0008 , A61K47/62 , A61K47/6923 , A61K47/6929 , A61K47/6937 , G01N33/505 , G01N2800/24
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括使用生物相容性生物可吸收纳米球根据T细胞的抗原特异性选择性还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

162. 发明申请

US20120027861A1 Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex, and method for treating cancer by using the pharmaceutical composition 有权
标题翻译：纳米载体，抗癌药物和纳米载体的复合物，其药物组合物，制造复合物的方法和使用药物组合物治疗癌症的方法
公开(公告)号：US20120027861A1
公开(公告)日：2012-02-02
申请号：US12805424
申请日：2010-07-30
申请人： Dar-Bin Shieh , Chen-Sheng Yeh , Dong-Hwang Chen , Ya-Na Wu , Ping-Ching Wu
发明人： Dar-Bin Shieh , Chen-Sheng Yeh , Dong-Hwang Chen , Ya-Na Wu , Ping-Ching Wu
IPC分类号： A61K9/14 , A61K31/7088 , A61P35/00 , C07H21/04
CPC分类号： A61K31/7072 , A61K9/1676 , A61K47/6923 , A61K47/6929 , B82Y5/00
摘要： The present invention relates to a nano-carrier for an anticancer drug, which comprises: a metal nanoparticle; and a polynucleotide for connecting with an anticancer drug having a pyrimidine group or a purine group, wherein the polynucleotide connects to a surface of the metal nanoparticle, and the anticancer drug binds to the polynucleotide through the pyrimidine group or the purine group. In addition, the present invention also provides a complex of an anticancer drug and a nano-carrier, a pharmaceutical composition thereof, a method for manufacturing the complex, and a method for treating a cancer by using the pharmaceutical composition.
摘要翻译：本发明涉及抗癌药物的纳米载体，其包含：金属纳米粒子; 以及与具有嘧啶基或嘌呤基的抗癌药连接的多核苷酸，其中多核苷酸与金属纳米粒子的表面连接，抗癌药通过嘧啶基或嘌呤基与多核苷酸结合。此外，本发明还提供了抗癌药物和纳米载体的复合物，其药物组合物，该复合物的制造方法以及使用该药物组合物治疗癌症的方法。

163. 发明申请

US20120009130A1 Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques 审中-公开
标题翻译：使用纳米技术的病毒治疗和预防技术
公开(公告)号：US20120009130A1
公开(公告)日：2012-01-12
申请号：US13102808
申请日：2011-05-06
申请人： Krishnan Chakravarthy , Suryaprakash Sambhara , Paul Knight
发明人： Krishnan Chakravarthy , Suryaprakash Sambhara , Paul Knight
IPC分类号： A61K31/713 , A61P31/12 , C07H21/02 , A61K9/12 , B82Y5/00
CPC分类号： A61K31/713 , A61K47/6923 , A61K47/6931 , B82Y5/00 , C12N15/1131 , C12N2310/14 , C12N2310/351 , C12N2320/32
摘要： The present disclosure provides compositions and methods of enhancing resistance to viral infections through targeted delivery of 5′PPP negative stranded siRNA via nanoparticles, specifically gold nanorods. The 5′PPP activates type I interferon through the signaling cascade providing a novel therapeutic and prophylactic for seasonal and pandemic influenza. The technology described herein also extends the findings to the use of nanoparticles for delivery of genetic material including but not limited to siRNA and microRNA to accomplish targeted nanoparticle based gene therapy.
摘要翻译：本公开提供通过靶向通过纳米颗粒，特别是金纳米棒的5'PPP负链siRNA递送来增强对病毒感染的抗性的组合物和方法。 5'PPP通过信号级联激活I型干扰素，为季节性和大流行性流感提供新颖的治疗和预防。本文描述的技术还将研究结果扩展到使用纳米颗粒递送遗传物质，包括但不限于siRNA和微小RNA以完成基于靶向纳米颗粒的基因治疗。

164. 发明申请

US20110311453A1 Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto 有权
公开(公告)号：US20110311453A1
公开(公告)日：2011-12-22
申请号：US13157099
申请日：2011-06-09
申请人： Shuming Nie , Robert E. Bailey
发明人： Shuming Nie , Robert E. Bailey
IPC分类号： A61K49/00 , H01B1/02 , G01N33/53 , B82Y5/00 , B82Y30/00
CPC分类号： H01L29/2203 , A61K47/6923 , A61K49/0067 , B82Y5/00 , B82Y10/00 , B82Y15/00 , B82Y20/00 , B82Y30/00 , C01B19/002 , C01B19/007 , C01B21/0632 , C01P2002/01 , C01P2002/50 , C01P2002/72 , C01P2002/84 , C01P2002/85 , C01P2004/04 , C01P2004/64 , C01P2004/84 , C09K11/565 , C09K11/62 , C09K11/883 , C09K11/89 , G01N33/588 , H01L29/127 , H01L31/0352 , H01L31/03529 , Y02E10/50 , Y10S435/967
摘要： An alloyed semiconductor quantum dot comprising an alloy of at least two semiconductors, wherein the quantum dot has a homogeneous composition and is characterized by a band gap energy that is non-linearly related to the molar ratio of the at least two semiconductors; a series of alloyed semiconductor quantum dots related thereto; a concentration-gradient quantum dot comprising an alloy of a first semiconductor and a second semiconductor, wherein the concentration of the first semiconductor gradually increases from the core of the quantum dot to the surface of the quantum dot and the concentration of the second semiconductor gradually decreases from the core of the quantum dot to the surface of the quantum dot; a series of concentration-gradient quantum dots related thereto; in vitro and in vivo methods of use; and methods of producing the alloyed semiconductor and concentration-gradient quantum dots and the series of quantum dots related thereto.

165. 发明申请

US20110300221A1 Therapeutic Inhibitor of Vascular Smooth Muscle Cells 审中-公开
标题翻译：血管平滑肌细胞的治疗抑制剂
公开(公告)号：US20110300221A1
公开(公告)日：2011-12-08
申请号：US13209956
申请日：2011-08-15
申请人： Lawrence L. Kunz , Peter G. Anderson
发明人： Lawrence L. Kunz , Peter G. Anderson
IPC分类号： A61K9/14 , A61P7/00 , A61P9/08 , A61K31/337
CPC分类号： A61K31/04 , A61K9/0024 , A61K31/00 , A61K31/131 , A61K31/135 , A61K31/138 , A61K31/165 , A61K31/17 , A61K31/337 , A61K31/352 , A61K31/365 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/407 , A61K31/519 , A61K31/551 , A61K31/704 , A61K47/50 , A61K47/51 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6831 , A61K47/6843 , A61K47/6923 , A61K47/6927 , A61K47/6957 , A61L31/148 , A61L31/16 , A61L2300/416 , A61L2300/602 , A61L2300/604 , A61L2300/606 , B82Y5/00 , G01N2800/323 , Y10S977/775 , Y10S977/808 , Y10S977/905 , Y10S977/906 , Y10S977/916
摘要： Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
摘要翻译：提供了用于在哺乳动物宿主中的血管创伤或疾病之后抑制狭窄的方法，包括向宿主施用治疗有效剂量的含有血管平滑肌结合蛋白的治疗性缀合物，其以特定方式与血管平滑的细胞表面相关联肌肉细胞，与抑制肌肉细胞的细胞活性的治疗剂剂型偶联。还提供了用于通过抑制平滑肌细胞收缩导致血管腔的扩张和固定的血管平滑肌细胞的治疗剂的直接和/或靶向递送的方法，从而构成生物支架。

166. 发明授权

US08071132B2 Unagglomerated core/shell nanocomposite particles 有权
标题翻译：未凝聚的核/壳纳米复合材料颗粒
公开(公告)号：US08071132B2
公开(公告)日：2011-12-06
申请号：US11142913
申请日：2005-06-01
申请人： James H. Adair , Sarah M. Rouse , Jun Wang , Mark Kester , Christopher Siedlecki , William B. White , Erwin Vogler , Alan Snyder , Carlo G. Pantano , Victor Ruiz-Velasco , Lawrence Sinoway
发明人： James H. Adair , Sarah M. Rouse , Jun Wang , Mark Kester , Christopher Siedlecki , William B. White , Erwin Vogler , Alan Snyder , Carlo G. Pantano , Victor Ruiz-Velasco , Lawrence Sinoway
IPC分类号： A61K9/14
CPC分类号： A61K49/0041 , A61K47/6923 , A61K47/6929 , A61K49/0093 , B01J13/02 , B82Y5/00 , B82Y30/00 , Y10T428/2982 , Y10T428/2984 , Y10T428/2989 , Y10T428/2991 , Y10T428/2995
摘要： The present invention provides a method for the synthesis of unagglomerated, highly dispersed, stable core/shell nanocomposite particles comprised of preparing a reverse micelle microemulsion that contains nanocomposite particles, treating the microemulsion with a silane coupling agent, breaking the microemulsion to form a suspension of the nanocomposite particles by adding an acid/alcohol solution to the microemulsion that maintains the suspension of nanocomposite particles at a pH of between about 6 and 7, and simultaneously washing and dispersing the suspension of nanocomposite particles, preferably with a size exclusion HPLC system modified to ensure unagglomeration of the nanocomposite particles. The primary particle size of the nanocomposite particles can range in diameter from between about 1 to 100 nm, preferably from between about 10 to 50 nm, more preferably about 10 to 20 nm, and most preferably about 20 nm.
摘要翻译：本发明提供了一种用于合成非聚集的，高度分散的，稳定的核/壳纳米复合材料颗粒的方法，其包括制备含有纳米复合颗粒的反胶束微乳液，用硅烷偶联剂处理微乳液，破碎微乳液以形成悬浮液该纳米复合颗粒通过向微乳液中加入酸/醇溶液，将纳米复合材料颗粒的悬浮液保持在约6和7之间的pH，同时洗涤和分散纳米复合颗粒的悬浮液，优选用尺寸排阻HPLC系统修饰为确保纳米复合材料颗粒的团聚。纳米复合材料颗粒的一次粒径可以在约1至100nm之间，优选约10至50nm，更优选约10至20nm，最优选约20nm的范围内。

167. 发明授权

US08062675B2 Mesenchymal precursor cell 有权
标题翻译：间充质前体细胞
公开(公告)号：US08062675B2
公开(公告)日：2011-11-22
申请号：US12660003
申请日：2010-02-17
申请人： Stan Gronthos , Andrew Zannettino , Paul Simmons
发明人： Stan Gronthos , Andrew Zannettino , Paul Simmons
IPC分类号： A61K35/26
CPC分类号： A61K35/28 , A61K47/48861 , A61K47/6923 , A61K48/00 , A61K2035/124 , C12N5/0663 , C12N2500/42 , C12N2501/39
摘要： A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.
摘要翻译：一种富含间充质前体细胞的方法，包括基于至少两种标记物富集细胞的步骤。标记可能是i）对间质前体细胞特异性标志物的存在，ii）不存在对分化的间充质细胞特异性的标记，或iii）对间充质前体细胞特异的标志物的表达水平。该方法可以包括利用识别STRO-1 Mab抗原表达的MACS的第一固相分选步骤，随后使用两色FACS来筛选高水平STRO-1抗原表达的存在的第二分选步骤，以及 VCAM-1的表达。

168. 发明申请

US20110274757A1 NUCLEIC ACID DELIVERY VEHICLE AND USES THEREOF 有权
标题翻译：核酸递送车辆及其用途
公开(公告)号：US20110274757A1
公开(公告)日：2011-11-10
申请号：US12773478
申请日：2010-05-04
申请人： John Richard Nelson , Timothy James Yosenick
发明人： John Richard Nelson , Timothy James Yosenick
IPC分类号： A61K9/14 , A61P37/04 , A61K39/00 , A61K31/711 , A61K31/7105
CPC分类号： A61K31/7105 , A61K9/0019 , A61K9/1611 , A61K31/7088 , A61K31/711 , A61K33/26 , A61K45/06 , A61K47/6923 , A61K2039/53 , A61M35/00 , A61K2300/00
摘要： A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm. Methods of making the nucleic acid-delivery vehicle and kits comprising nucleic acid-delivery vehicle are also provided.
摘要翻译：提供了用于将核酸递送至靶细胞的核酸递送载体。核酸递送载体包含多个纳米颗粒; 和多个核酸。纳米颗粒和核酸被聚集以形成具有至少5nm的尺寸的核酸制粒颗粒。还提供了制备核酸递送载体和包含核酸递送载体的试剂盒的方法。

169. 发明申请

US20110262347A1 METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS 审中-公开
标题翻译：化合物增强方法和组合物
公开(公告)号：US20110262347A1
公开(公告)日：2011-10-27
申请号：US13083176
申请日：2011-04-08
申请人： Erkki Ruoslahti , Lilach Agemy , Dinorah Friedmann-Morviniski , Venkata Ramana Kotamraju , Kazuki Sugahara , Inder Verma
发明人： Erkki Ruoslahti , Lilach Agemy , Dinorah Friedmann-Morviniski , Venkata Ramana Kotamraju , Kazuki Sugahara , Inder Verma
IPC分类号： A61K51/00 , C07K7/08 , C07K14/76 , A61K47/42 , A61K9/127 , C07F13/00 , C07H21/00 , A61K38/16 , A61K31/7088 , A61K31/28 , C07D305/14 , A61K31/337 , A61K49/00 , A61P35/00 , A61P43/00 , C07K7/06 , B82Y5/00
CPC分类号： A61K38/04 , A61K47/55 , A61K47/66 , A61K47/6923 , B82Y5/00
摘要： Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
摘要翻译：公开了与针对细胞和组织的多价组合物相关的组合物和方法。所公开的靶向对于治疗癌症和其它疾病和病症是有用的。

170. 发明申请

US20110229966A1 Nanoparticle-Based Gene Delivery Systems 有权
标题翻译：基于纳米粒子的基因递送系统
公开(公告)号：US20110229966A1
公开(公告)日：2011-09-22
申请号：US12809996
申请日：2010-03-18
申请人： Min Su Han , Kangseok Lee , Dong-Eun Kim
发明人： Min Su Han , Kangseok Lee , Dong-Eun Kim
IPC分类号： C12N5/00
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/713 , A61K47/6923 , C12N15/111 , C12N15/87 , C12N15/89 , C12N2310/11 , C12N2310/127 , C12N2310/14 , C12N2310/351 , C12N2310/51 , C12N2310/531 , C12N2320/32 , Y10S977/773
摘要： The present invention provides a gene delivery system containing nanoparticles. In more detail, the present invention provides a gene delivery system containing (a) a nanomaterial; (b) an oligonucleotide as an universal binding partner covalently linked to the surface of the nanomaterial; and (c) a cargo comprising (i) a complementary oligonucleotide containing a nucleotide sequence complementary to the universal binding partner as a binding counter-partner, and (ii) an inhibitory molecule having a nucleotide sequence complementary to a target gene of interest to be inhibited or an inducible molecule having a nucleotide sequence of a target gene of interest to be expressed. The present invention is a gene delivery system capable of feasibly deliver aptamer, siRNA, shRNA, miRNA, ribozyme, DNAzyme, PNA or gene as well as antisense oligonucleotide into the cells. In addition, the present invention is more efficient than the commercially available gene transfer reagent in respect to the degree of knockdown of target protein expression.
摘要翻译：本发明提供含有纳米颗粒的基因递送系统。更详细地，本发明提供了一种基因递送系统，其包含（a）纳米材料; （b）与纳米材料的表面共价连接的通用结合配偶体的寡核苷酸; （c）货物，其包含（i）含有与通用结合配偶体互补的核苷酸序列作为结合对配体的互补寡核苷酸，和（ii）具有与目的靶基因互补的核苷酸序列的抑制性分子，或具有待表达的靶基因的核苷酸序列的诱导型分子。本发明是能够将适体，siRNA，shRNA，miRNA，核酶，DNA酶，PNA或基因以及反义寡核苷酸可行地递送到细胞中的基因递送系统。此外，与靶蛋白质表达的敲低程度相比，本发明比市售的基因转移试剂更有效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式